Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic...

Area of Science:

• Oncology
• Medical Oncology
• Clinical Trials

Background:

• Current second-line treatments for non-small cell lung cancer (NSCLC) include chemotherapy (docetaxel, pemetrexed) and targeted therapy (erlotinib).
• Emerging molecular drugs and alternative pathways (c-MET, ALK inhibitors) are being investigated to overcome resistance to established therapies.
• Predictive factors, such as EGFR mutations, are increasingly vital for selecting appropriate drugs and patients.

Purpose of the Study:

• To review clinical trials comparing targeted therapies with the standard of care for second-line treatment in advanced NSCLC.
• To highlight the importance of patient stratification based on predictive factors for optimizing treatment outcomes.

Main Methods:

• Systematic review of existing clinical trials.
• Analysis of studies comparing targeted therapies against standard-of-care agents.
• Evaluation of predictive biomarkers for patient selection.

Main Results:

• New molecular drugs are entering clinical trials, offering alternatives to standard chemotherapy and erlotinib.
• Targeted therapies show promise, particularly when selected based on specific molecular alterations.
• Investigating alternative pathways and predictive factors is crucial for managing treatment resistance.

Conclusions:

• Patient selection based on predictive factors allows for tailored second-line NSCLC treatment.
• Targeted therapies represent a significant advancement in managing advanced NSCLC, offering benefits in specific patient subgroups.
• Ongoing research into novel agents and resistance mechanisms will further refine second-line treatment strategies.